Ontology highlight
ABSTRACT:
SUBMITTER: Brullo C
PROVIDER: S-EPMC8303217 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
Brullo Chiara C Villa Carla C Tasso Bruno B Russo Eleonora E Spallarossa Andrea A
International journal of molecular sciences 20210716 14
In the past few years, Bruton's tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk inhibitors have been launched on the market. In the attempt to overcome irreversible Btk inhibitor limitations, reversible compounds have been developed and are currently under evaluation. In recent years, many Btk inhibitors have been patented and repor ...[more]